Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCARDIOVASCULAR PHARMACOLOGY

Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes

Frank Anastasopoulos, Randal Leung, Athena Kladis, Gail M. James, Todd A. Briscoe, Thaddeus P. Gorski and Duncan J. Campbell
Journal of Pharmacology and Experimental Therapeutics March 1998, 284 (3) 799-805;
Frank Anastasopoulos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Randal Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Athena Kladis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gail M. James
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd A. Briscoe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thaddeus P. Gorski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duncan J. Campbell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Dual inhibition of neutral endopeptidase 24.11 (NEP) and angiotensin-converting enzyme (ACE) offers the potential for improved therapy of hypertension and cardiac failure. S 21402–1 {(2S)-2-[(2S,3R)-2-thiomethyl-3-phenylbutanamido] propionic acid} is a sulfhydryl-containing potent inhibitor of both NEP (Ki = 1.7 nM) and ACE (Ki = 4.5 nM). S 21402–1 and the sulfhydryl-containing ACE inhibitor captopril were administered to rats by intraperitoneal injection (0, 0.3, 3, 30, 300 mg/kg). Urine was collected for 4 h; then plasma and kidneys were collected. The difference in NEP and ACE inhibition by S 21402–1 in vivo was greater than 1000-fold. All doses of S 21402–1 inhibited NEP, as indicated by plasma NEP activity, radioinhibitor binding to kidney sections, urinary sodium excretion and bradykinin-(1–7)/bradykinin-(1–9) ratio. However, only 300 mg/kg S 21402–1 inhibited ACE, as indicated by plasma angiotensin II/angiotensin I ratio, renin and angiotensinogen levels. Although S 21402–1 (30 and 300 mg/kg) inhibited renal NEP, as indicated by the bradykinin-(1–7)/bradykinin-(1–9) ratio in kidney, S 21402–1 had no effect on renal ACE, as indicated by the angiotensin II/angiotensin I ratio in kidney. Moreover, captopril was greater than 10-fold more potent than S 21402–1 as an ACE inhibitor in vivo. In separate experiments, the pressor response of anesthetized rats to angiotensin I showed more rapid decay in ACE inhibition by S 21402–1 than by captopril. These studies indicated that in vivomodification of S 21402–1 caused a much greater decrease in potency of ACE inhibition than NEP inhibition. Consequently, effective ACE inhibition by S 21402–1 required doses much higher than those required for NEP inhibition.

Footnotes

  • Send reprint requests to: Dr. D. J. Campbell, St. Vincent’s Institute of Medical Research, 41 Victoria Parade, Fitzroy, Victoria 3065, Australia.

  • ↵1 This study was funded by a grant from the National Health and Medical Research Council of Australia.

  • Abbreviations:
    ACE
    angiotensin-converting enzyme
    Ang I
    angiotensin I
    Ang II
    angiotensin II
    ANP
    atrial natriuretic peptide
    BK-(1–7)
    bradykinin-(1–7)
    BK-(1–8)
    bradykinin-(1–8)
    BK-(1–9)
    bradykinin-(1–9)
    GMP
    guanosine monophosphate
    HPLC
    high-performance liquid chromatography
    NEP
    neutral endopeptidase
    RB104
    2-[(3-iodo-4-hydroxy)phenylmethyl]-4-N-[3-(hydroxyamino-3-oxo-1-phenylmethyl)propyl]amino-4-oxobutanoic acid
    RIA
    radioimmunoassay
    S 21402–1
    (2S)-2-[(2S,3R)-2-thiomethyl-3-phenylbutanamido] propionic acid
    • Received June 2, 1997.
    • Accepted November 10, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 3
1 Mar 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCARDIOVASCULAR PHARMACOLOGY

Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes

Frank Anastasopoulos, Randal Leung, Athena Kladis, Gail M. James, Todd A. Briscoe, Thaddeus P. Gorski and Duncan J. Campbell
Journal of Pharmacology and Experimental Therapeutics March 1, 1998, 284 (3) 799-805;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCARDIOVASCULAR PHARMACOLOGY

Marked Difference between Angiotensin-Converting Enzyme and Neutral Endopeptidase Inhibition in Vivo by a Dual Inhibitor of Both Enzymes

Frank Anastasopoulos, Randal Leung, Athena Kladis, Gail M. James, Todd A. Briscoe, Thaddeus P. Gorski and Duncan J. Campbell
Journal of Pharmacology and Experimental Therapeutics March 1, 1998, 284 (3) 799-805;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • TAS-301, an Inhibitor of Smooth Muscle Cell Migration and Proliferation, Inhibits Intimal Thickening after Balloon Injury to Rat Carotid Arteries
  • Identification of Low Molecular Weight GP IIb/IIIa Antagonists That Bind Preferentially to Activated Platelets
  • Differential Contribution of Angiotensinergic and Cholinergic Receptors in the Hypothalamic Paraventricular Nucleus to Osmotically Induced AVP Release
Show more CARDIOVASCULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics